Sign In
Learn bits
Health & Medicine
Mahesh

07/09/22 13:51 PM IST

India's first intranasal Covid vaccine by Bharat Biotech gets DCGI approval

In News 
  • India's first intranasal Covid vaccine by Bharat Biotech received DCGI approval for primary immunization against the infection for people above the age of 18.
About Intranasal Vaccine 
  • The intranasal vaccine for COVID-19 by Bharat Biotech is first of its kind needle-free vaccine.
  • Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.
iNCOVACC
  • The iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein.
  • This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results.
  • This vaccine has been specifically formulated to allow intranasal delivery through nasal drops.
  • The nasal delivery system has been designed and developed to be cost-effective in low and middle-income countries.
  • The intranasal vaccine is a heterologous booster dose.
Source- Live Mint 

More Related Current Affairs View All

22 Aug

Uttarakhand State Authority for Minority Education (USAME) Bill, 2025

'The Uttarakhand Assembly on Wednesday passed the Minority Education Bill, 2025, extending minority status benefits to institutions run by the Sikh, Jain, Buddhist, Christian, and

Read More

22 Aug

India needs a national space law urgently

'A nation with a strong base in science and technology is a nation with a strong backbone” — these words of A.P.J. Abdul Kalam ring truer than before as India celebrate

Read More

22 Aug

Organ transplantation

'The National Organ and Tissue Transplant Organisation (NOTTO) recently issued a direction stating that women patients and relatives of deceased donors will receive priority in org

Read More

India’s First Ai-Driven Magazine Generator

Generate Your Custom Current Affairs Magazine using our AI in just 3 steps